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ABSTRACT
Background: There are few available reports in the literature 
assessing in-hospital outcomes of diabetic patients currently 
undergoing percutaneous coronary intervention (PCI). This 
article aimed to assess the acute post-PCI outcomes of a 
large series of diabetic and non-diabetic patients treated 
consecutively. Methods: From August 2006 to February 
2012, 6,011 patients were submitted to PCI and included 
in the registry of the Hospital Bandeirantes. The techniques 
and devices for the procedure were chosen by the sur-
geons. Clinical outcomes were registered at the time of 
hospital discharge. Results: Diabetic patients were older 
and more frequently females, with a higher prevalence of 
comorbidities and risk factors for coronary artery disease, 
except for smoking. However, most of the characteristics 
related to lesion complexity did not differ between groups. 
In diabetics, the number of treated vessels (1.6  ±  0.8 vs. 
1.4  ±  0.7; P  <  0.01) was higher, and the use of smaller 
stents (2.9 ± 0.5 mm vs. 3 ± 0.5 mm; P < 0.01) was more 
frequent. A procedural success rate of 95.5% was achieved 
in both groups. In-hospital outcomes did not differ in the 
incidence of major adverse cardiac and cerebrovascular events 
(3.3% vs. 2.8%; P = 0.79), death (1% vs. 1.1%; P = 0.90), 
acute myocardial infarction (2% vs. 2.4%; P = 0.35), stroke 
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RESUMO
Resultados Hospitalares da Intervenção  
Coronária Percutânea em Diabéticos
Introdução: Poucas publicações estão disponíveis na litera tura 
avaliando a evolução hospitalar de pacientes diabéticos submetidos 
a intervenção coronária percutânea (ICP) na era contemporânea. 
Nosso objetivo foi avaliar os resultados agudos pós-ICP de uma 
grande série de pacientes diabéticos e não  diabéticos, tratados 
consecutivamente. Métodos: No período de agosto de 2006 a 
fevereiro de 2012, 6.011 pacientes foram submetidos a ICP e 
incluídos no Registro do Hospital Bandeirantes. A técnica e a 
escolha do material durante o procedimento ficaram a cargo dos 
operadores. Os desfechos clínicos foram registrados no momento 
da alta hospitalar. Resultados: Os diabéticos mostraram ser mais 
idosos, mais frequentemente do sexo feminino, com maior 
prevalência de comorbidades e fatores de risco para doença 
arterial coro nária, à exceção do tabagismo. A maioria das carac-
terísticas de complexidade das lesões, no entanto, não diferiu 
entre os grupos. Nos diabéticos, o número de vasos tratados 
(1,6 ± 0,8 vs. 1,4 ± 0,7; P < 0,01) foi maior e o uso de stents 
de menor calibre (2,9 ± 0,5 mm vs. 3 ± 0,5 mm; P < 0,01) 
foi mais frequente. Taxa de sucesso do procedimento de 95,5% 
foi alcançada nos dois grupos. Os desfechos hospitalares não 
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(0.1% in both groups), and emergency revascularisation 
(0.3% in both groups). Arterial hypertension was the vari-
able that best explained the occurrence of major adverse 
cardiac and cerebrovascular events [odds ratio (OR): 2.68, 
95% confidence interval (95% CI): 1.13–6.38; P  =  0.026). 
Conclusions: Diabetes mellitus adds more clinical complexity 
to PCI but has no significant impact on in-hospital outcomes.
 
 
 
 
DESCRIPTORS: Diabetes mellitus. Angioplasty. Stents.
T he number of diabetic individuals is increasing due to population growth and aging, greater urbanisation, and higher prevalence of obesity 
and sedentary lifestyle. Type 2 diabetes has become a 
global epidemic, with an estimated 173 million diabetic 
individuals in 2002. This number is projected to reach 
300 million in 2030.1
Diabetes is a known risk factor for the development 
of atherosclerosis, which is a major cause of morta-
lity in this group of patients.2 Patients with diabetes 
mellitus are at increased risk of cardiovascular events 
and death compared with those without the disease 
and account for approximately one-third of patients 
undergoing percutaneous coronary intervention (PCI) 
in the United States.3
Percutaneous and surgical myocardial revascularisation 
therapies are important tools in the treatment of coronary 
artery disease, which impacts quality of life and survival. 
Results among diabetics, however, are less pronounced, 
with a greater occurrence of new revascularisations in 
late follow-up, especially in patients with multivessel 
disease.4 The comple xity of coronary  lesions, the rapid 
progression of atherosclerotic disease, and the higher 
rates of restenosis, even when using drug-eluting stents, 
are some of the reasons for these results.
However, few studies are currently available regarding 
the in-hospital results of PCI in diabetic patients. This 
article aimed to evaluate the acute post-PCI outcomes 
of a large series of consecutively treated diabetic and 
non-diabetic patients.
METHODS
Patients
From August, 2006 to February, 2012, 6,011 con-
secutive patients underwent PCI and were included in 
the Hospital Bandeirantes Registry. Data were collected 
prospectively and stored in a computerised database.
Clinical outcomes were registered at the time of 
hospital discharge.
mostraram diferenças quanto à incidência de eventos cardíacos 
e cerebrovasculares adversos maiores (3,3% vs. 2,8%; P = 0,79), 
óbito (1% vs. 1,1%; P = 0,90), infarto agudo do miocárdio (2% 
vs. 2,4%; P = 0,35), acidente vascular cerebral (0,1% em ambos 
os grupos), e revascularização de emergência (0,3% em ambos os 
grupos). Hipertensão arterial foi a variável que melhor explicou 
a ocorrência de eventos cardíacos e cerebrovasculares adversos 
maiores [odds ratio (OR) 2,68, intervalo de confiança de 95% 
(IC 95%) 1,13 6,38; P = 0,026). Conclusões: O diabetes agrega 
maior complexi dade clínica à ICP, sem modificar, entretanto, 
os desfechos clínicos hospitalares.
DESCRITORES: Diabetes mellitus. Angioplastia. Stents.
PCI
Almost all interventions were conducted by femoral 
access, and radial access was used as an alternative in 
a few cases. The materials and technique used during 
the procedure and the need for glycoprotein IIb/IIIa 
inhibitors were chosen by the surgeons. Unfractionated 
heparin was used at the beginning of the procedure 
at a dose of 70  U/kg to 100  U/kg, except in patients 
who were already using low molecular-weight heparin.
All patients received antiplatelet therapy in combina-
tion with acetylsalicylic acid (ASA) with a loading dose 
of 300 mg and a maintenance dose of 100 mg/day to 
200 mg/day and a clopidogrel loading dose of 300 mg 
to 600  mg with a maintenance dose of 75  mg/day. 
The femoral sheaths were removed four hours after the 
start of heparinisation. The radial sheaths were removed 
immediately after the procedure.
Angiographic analysis and definitions
The analyses were performed in at least two or-
thogonal projections by experienced technicians using 
digital quantitative angiography. This study used the 
same angiographic criteria listed in the database of the 
National Centre of Cardiovascular Interventions (Central 
Nacional de Intervenções Cardiovasculares – CENIC) of 
the Brazilian Society of Interventional Cardiology. The 
type of lesion was classified according to the criteria 
of the American College of Cardiology and  the Ameri-
can Heart Association (ACC/AHA).5 The thrombolysis 
in myocardial infarction (TIMI) classification was used 
to determine the pre- and post-procedural coronary 
flow.6 Procedural success was defined as achievement 
of angiographic success (residual stenosis <  30% with 
TIMI flow 3) and absen ce of major adverse cardiac and 
cerebrovascular events (MACCE) comprising death, peri-
procedural myocardial infarction, stroke, and emergency 
coronary artery bypass graft (CABG) surgery.7
Deaths from any cause were recorded, and cardiac 
mortality was defined as mortality resulting from cardio-
genic shock, heart failure, acute myocardial infarction 
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(AMI), cardiac rupture, arrhythmia, or sudden death 
during the hospitalisation period. Peri-PCI infarction 
was defined by the reappearance of angina symptoms 
with electrocardiographic alterations (new ST-segment 
elevation or new Q waves) and/or angiographic evi-
dence of target vessel occlusion. Emergency CABG was 
considered when performed immediately after the PCI.
Statistical analysis
The data, stored in an Oracle database, were Oracle 
database were plotted in Excel spreadsheets and analysed 
using the Statistical Package for Social Sciences (SPSS), 
release 15.0. Continuous variables were expressed as 
the mean ± standard deviation, and categorical variables 
were expressed as absolute numbers and percentages. 
Associations between continuous variables were eva-
luated using the analysis of variance (ANOVA) model. 
Associations between categorical variables were evalu-
ated by chi-aquared or Fisher’s exact tests or likelihood 
ratios when appropriate. The level of significance was 
set at P < 0.05. Simple and multiple logistic regression 
models were applied to identify MACCE predictors.
RESULTS
The clinical characteristics are shown in Table 
1. The diabetic group was 3 years older (64.1 years 
vs. 60.9 years; P  <  0.01), with a higher proportion 
of women (37.1% vs. 29.4%; P  <  0.01) and a higher 
body mass index (28 ± 4.8 kg/m2 vs. 26.8 ± 4.3 kg/m2; 
P  <  0.01) compared with non-diabetics. Moreover, 
diabetics had a predominance of hypertension (86.4% 
vs. 69.3%; P < 0.01), dyslipidemia (47.9% vs. 30.4%; 
P < 0.01), chronic kidney failure (4.2% vs. 2%; P < 0.01), 
peripheral vascular disease (4.4% vs. 2%; P  <  0.01), 
previous AMI (19.2% vs. 15.4%; P < 0.01), stroke (3.9% 
vs. 2.6%; P < 0.01), CABG (15.6% vs. 8.6%; P < 0.01), 
and PCI (23.9% vs. 18.8%; P < 0.01). Smoking was the 
only coronary risk factor that was predominant among 
non-diabetics (17% vs. 28.3%; P < 0.01). The clinical 
presentation was different between groups (P  <  0.01); 
acute coronary syndrome without ST segment elevation 
was more frequent in the diabetic group (22.6% vs. 
18.7%) and AMI with ST segment elevation was more 
frequent in the non-diabetic group (19.4% vs. 26%).
Regarding the pre-intervention cardiovascular medica-
tion, diabetics more frequently used acetylsalicylic acid 
(51.1% vs. 41.8%; P  <  0.01), clopidogrel (30.2% vs. 
24.6%; P < 0.01), statins (38.4% vs. 29.4%; P < 0.01), 
and angiotensin-converting enzyme inhibitors (32.6% vs. 
25%; P  <  0.01). The use of glycoprotein IIb/IIIa inhibi-
tors during the procedure did not differ between groups.
Table 2 shows the angiographic characteristics. There 
was a predominance of multivessel disease, with lesions 
in two or three vessels in diabetics (31.2% vs. 28% and 
19% vs. 10.4%, respectively; P < 0.01). The left anterior 
descending artery was the most frequently approached 
vessel in both groups (39.1% vs. 34%; P < 0.01). The 
interventions were mostly performed in B2/C lesions (53.9% 
vs. 56.9%; P  =  0.08), and most of the characteristics 
of lesion complexity did not differ between the groups. 
However, the presence of thrombi in the treated lesion 
(7.8% vs. 11%; P < 0.01) and the TIMI flow 0/1 in the 
vessel to be treated (14.7% vs. 19.6%; P  <  0.01) was 
lower in the diabetic group.
The diabetic group showed a higher number of 
treated vessels and greater use of drug-eluting stents 
(26.9% vs. 15%; P < 0.01) (Table 3). The angiographic 
quantification of obstructions before the procedure 
showed a higher percentage of luminal obstruction 
by plaque among non-diabetics (82.8  ±  12.6  mm vs. 
84.4 ± 12.8 mm; P < 0.01), with no differences between 
the groups regarding the quantification of obstruction 
after the procedure. The stents implanted in the dia-
betic group had a smaller diameter (2.9 ± 0.5 mm vs. 
3  ±  0.5  mm; P  <  0.01), with no difference regarding 
length compared with non-diabetics (18.2  ±  6.9  mm 
vs. 18.5  ±  6.8  mm; P  =  0.23). A high rate (95.5%) of 
procedural success was achieved in both groups.
The in-hospital outcomes (Table 4) of PCI showed 
no differences between the groups in the incidence of 
MACCE (3.3% vs. 2.8%; P  =  0.79) or occurrence of 
in-hospital death (1% vs. 1.1%; P  =  0.90), AMI (2% 
vs. 2.4%; P = 0.35), stroke (0.1% in both groups), and 
new emergency intervention (PCI or CABG) (0.3% in 
both groups).
Age, hypertension, previous stroke, use of glycoprotein 
IIb/IIIa inhibitors, acute coronary syndrome, extension of 
the obstructive coronary disease, lesions with thrombus, 
pre-intervention TIMI flow, number of treated vessels, 
and long lesions and type B2/C lesions had a signifi-
cant association with the occurrence of events in the 
univariate analysis; only hypertension [odds ratio (OR): 
2.68, 95% confidence interval (95% CI): 1.13–6.38; 
P  =  0.026)] was the variable that best explained the 
presence of MACCE in the studied population.
DISCUSSION
The presence of diabetes mellitus in patients with 
atherosclerotic disease is a marker of poor prognosis 
when they are submitted to PCI, with a higher incidence 
of complications and restenosis.8–10 It is believed that 
this is due to endothelial and metabolic alterations, 
which lead to a greater chance of atherosclerotic 
plaque rupture and thrombus formation and increased 
exacerbation of intimal hyperplasia.10–12 In the present 
study, the impact of diabetes mellitus on in-hospital 
outcomes was evaluated in a large cohort of patients 
currently undergoing PCI.
According to the clinical characteristics of patients, 
most cardiovascular risk factors and comorbidities were 
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TABLE 1  
Clinical Characteristics
Characteristic
Diabetics
(n = 1,808)
Non-diabetics
(n = 4,203) P 
Age, years
Female gender, n (%)
Arterial hypertension, n (%)
Dyslipidemia, n (%)
Smoking, n (%)
Previous AMI, n (%)
Previous PCI, n (%)
Previous CABG, n (%)
Previous stroke, n (%)
Chronic kidney failure, n (%)
Peripheral vascular disease, n (%)
Mean BMI, kg/m²
Clinical presentation, n (%)
 Asymptomatic
 Stable angina
 Acute coronary syndrome without ST elevation
 AMI
 Ischemic equivalent
TIMI score for acute coronary syndrome, n (%)
 Low risk
 Medium risk
 High risk
Primary PCI, n (%)
AMI Killip, n (%)
 I
 II
 III
 IV
Adjunct medication, n (%)
 Acetyl salicylic acid
 Clopidogrel
 Statin
 Angiotensin-converting enzyme inhibitor
 Glycoprotein IIb/IIIa inhibitors
64.1 ± 10.8
671 (37.1)
1,562 (86.4)
866 (47.9)
307 (17)
348 (19.2)
432 (23.9)
282 (15.6)
70 (3.9)
76 (4.2)
80 (4.4)
28 ± 4.8
522 (28.9)
494 (27.3)
407 (22.6)
350 (19.4)
35 (1.9)
100 (34.4)
124 (42.8)
67 (23)
129 (7.1)
125 (68.7)
31 (17)
7 (3.8)
19 (10.4)
924 (51.1)
546 (30.2)
694 (38.4)
590 (32.6)
31 (3)
60.9 ± 12.2
1,237 (29.4)
2,912 (69.3)
1,276 (30.4)
1,190 (28.3)
646 (15.4)
790 (18.8)
362 (8.6)
109 (2.6)
82 (2)
83 (2)
26.8 ± 4.3
1,199 (28.5)
1,061 (25.3)
787 (18.7)
1,091 (26)
65 (1.5)
315 (52.2)
230 (38.1)
58 (9.6)
407 (9.7)
433 (75.8)
76 (13.3)
15 (2.6)
47 (8.2)
1,757 (41.8)
1,035 (24.6)
1,237 (29.4)
1,051 (25)
84 (3.1)
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
0.01
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
0.29
< 0.01
< 0.01
< 0.01
< 0.01
0.84
AMI = acute myocardial infarction; PCI = percutaneous coronary intervention; BMI = body mass index; CABG = coronary artery bypass 
graft; TIMI = thrombolysis in myocardial infarction.
more common in diabetics, which would indicate a 
poor clinical outcome in this group.8–12 However, the 
present findings demonstrated no influence of diabetes 
on clinically adverse events at the hospitalisation phase, 
despite the greater clinical complexity of patients. The 
angiographic profile of diabetic patients, however, showed 
no diffe rence for most analysed variables compared with 
non-diabetics, which suggests that the appropriate choice 
of cases attenuated the higher number of in-hospital 
events expected for that group.
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TABLE 2 
Angiographic Characteristics
Characteristic
Diabetics
(n = 1,808 patients/ 2,892 lesions)
Non-diabetics
(n = 4,203 patients/ 5,230 lesions) P 
Affected vessels, n (%) < 0.01
 One 548 (47.4) 1,800 (59.9)
 Two 361 (31.2) 843 (28)
 Three 220 (19) 314 (10.4)
Treated vessel, n (%) < 0.01
 RCA 548 (23.4) 1,996 (22.2)
 ADA 606 (39.1) 2,410 (34)
 Cx 358 (12.1) 1,204 (11.6)
 LCA 49 (1.6) 27 (2.3)
Calcified lesions, n (%) 989 (34.2) 1,699 (32.5) 0.23
Type B2/C lesions, n (%) 1,558 (53.9) 2,975 (56.9) 0.08
Lesions > 20 mm, n (%) 326 (11.3) 564 (10.8) 0.65
Bifurcations, n (%) 196 (6.8) 445 (8.5) 0.03
Lesions with thrombi, n (%) 225 (7.8) 575 (11) < 0.01
Left ventricular dysfunction, n (%) 196 (32.6) 523 (35) 0.39
Pre-PCI TIMI flow < 0.01
 TIMI 0/1, n (%) 267 (14.7) 820 (19.6)
 TIMI 2/3, n (%) 1,540 (85.2) 3,379 (80.5)
Total treated vessels 1.6 ± 0.8 1.4 ± 0.7 < 0.01
RCA = right coronary artery; Cx = circumflex artery; ADA = anterior descending artery; PCI = percutaneous coronary intervention;  
TIMI = thrombolysis in myocardial infarction.
TABLE 3 
Procedural Characteristics
Characteristic
Diabetics
(n = 1,808)
Non-diabetics
(n = 4,203) P 
Bare-metal stents, n (%) 1,258 (73.1) 3,401 (85) < 0.01
Drug-eluting stents, n (%) 462 (26.9) 600 (15) < 0.01
Stent diameter, mm  2.9 ± 0.5 3 ± 0.5 < 0.01
Stent length, mm 18.2 ± 6.9 18.5 ± 6.8 0.23
Degree of pre-procedural stenosis, % 82.8 ± 12.6 84.4 ± 12.8 < 0.01
Degree of post-procedural stenosis, % 0.9 ± 6.8 1 ± 7.4 0.69
Procedural success, n (%) 1,727 (95.5) 4,015 (95.5) > 0.99
TABLE 4 
In-hospital Clinical Outcomes
Characteristic
Diabetics
(n = 1,808)
Non-diabetics
(n = 4,203) P 
MACCE, n (%) 60 (3.3) 120 (2.8) 0.79
Overall mortality, n (%) 18 (1) 45 (1.1) 0.90
AMI post-PCI, n (%) 36 (2) 102 (2.4) 0.35
Stroke, n (%) 2 (0.1) 5 (0.1) > 0.99
Emergency CABG or PCI, n (%) 6 (0.3) 14 (0.3) > 0.99
MACCE = major adverse cardiac and cerebrovascular events; AMI = acute myocardial infarction; PCI = percutaneous coronary intervention; 
CABG = coronary artery bypass graft.
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The present findings are consistent with previous 
studies, such as that by Stein et al.,13 in which elective 
angioplasties of 1,133 diabetics and 9,300 non-diabetic 
patients between 1980 and 1990 were analysed. Similarly, 
the authors observed that diabetics were older, were 
more often females, and had a history of previous AMI, 
arterial hypertension, and multivessel involvement. In this 
study, there was no difference regarding the in-hospital 
clinical outcomes between diabetics and non-diabetics.
In a recent study, Li et al.14 evaluated 1,294 patients 
and found a higher incidence of acute/subacute in-stent 
thrombosis in the diabetic group. However, as in the 
present study, the presence of diabetes mellitus was 
not an independent predictor of cardiovascular events 
during hospitalisation.
In contrast, according to the database of the National 
Cardiovascular Data Registry (NCDR), which covered 
procedures performed from 2004 to 2007, the rate of 
overall in-hospital mortality was 1.27%, and the pres-
ence of diabetes mellitus was an independent predictor 
of in-hospital mortality after PCI.15–17
The observation of a poorer prognosis in diabetic 
patients is more consistent in the late outcome after PCI, 
which may be explained by higher rates of restenosis 
and disease progression in this group of patients.1,8–10 In 
Brazil, the Drug-Eluting Stent in the Real World (DESIRE 
registry),18 which assessed the predictors of target lesion 
revascularisation in a long-term clinical follow-up, dem-
onstrated that diabetes mellitus predisposes individuals 
to a greater need for new procedures. A subanalysis 
of the same registry, which evaluated the late outcome 
after PCI with drug-eluting stents in diabetic patients, 
showed that, when analysed in combination, major 
cardiac events occurred more frequently in the diabetic 
group, although still at very low rates.19
Data from the BARI Registry, the Duke International 
Registry, and the Northern New England Study Group 
suggest that careful selection of diabetic patients for PCI 
can minimise the differences in results in relation to 
the modality of  surgical myocardial revascularisation, 
and the use of drug-eluting stents is thus imperative in 
this population.9,20 The study by Tanajura et al.,4 which 
assessed the influence of using drug-eluting stents in the 
selection of diabetic patients treated with PCI, observed 
a change in the profile of these patients, demonstrat-
ing that the increased availability of drug-eluting stents 
expands the indications for more complex cases and 
allows for a more complete myocardial revascularisation. 
In the present analysis, diabetic patients received more 
drug-eluting stents than non-diabetics in percentage 
terms, but this rate was not higher because the Brazilian 
Unified Health System (Sistema Único de Saúde – SUS) 
does not provide this technology to its users.
Study limitations
Limitations of this study include the retrospective 
analysis of data, its performance in a single centre, and 
the absence of late follow-up.
CONCLUSIONS
Diabetes mellitus adds more clinical complexity to 
patients treated by PCI, but does not modify in-hospital 
clinical outcomes.
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